Virax Biolabs Group Limited filings document a foreign private issuer developing immunology research and diagnostic technologies, including disclosures tied to the ViraxImmune platform and immune-profiling strategy. Form 6-K reports include shareholder letters, investor presentation exhibits, clinical and commercial framework updates, and statements on the company’s ordinary shares.
The filing record also covers capital-structure matters such as private placements, pre-funded warrants, preferred investment options and ordinary-share issuance. Governance disclosures include annual general meeting notices, proxy materials, shareholder voting and quorum matters, auditor ratification, director elections, board committee appointments, equity incentive plans, and amendments to memorandum and articles of association.
Virax Biolabs Group Ltd (VRAX) asks shareholders to approve a proposed 4-for-1 consolidation of its authorized, issued and outstanding ordinary shares on December 14, 2026 or a later date accepted by Nasdaq. The extraordinary meeting is November 27, 2026; holders of record on November 11, 2026 may vote. The company says it has not received a Nasdaq deficiency notice. Because it effected a 25-for-1 consolidation on June 26, 2026, the company says a closing bid below $1.00 for 30 consecutive business days would leave it ineligible for a compliance period, and Nasdaq would issue a Staff Delisting Determination.
If approved and the consolidation is effected, authorized share capital would rise from US$12,500,000 divided into 125,000,000 ordinary shares of US$0.10 each to US$50,000,000 divided into 500,000,000 such shares. The company says the increase is intended for operational financing and potential business development, and is conditional on the consolidation. A charter amendment is proposed subject to and immediately following the increase; shareholders will also consider adjournment if directors deem it necessary to seek more proxy votes. The board recommends FOR all four proposals. The company says the consolidation leaves proportional holdings unchanged except for fractional shares, which would be rounded up.
On October 29, 2026, Virax Biolabs Group Limited, through its wholly owned China subsidiary Shanghai Xitu Consulting Co., Ltd., entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. for ImmuneSelect research-use immune profiling products. The channels cover specified customer segments in Beijing, Shanghai, Hubei, Jiangsu, Anhui and Shandong.
The distributors will purchase products from Virax for resale and manage local sales, customer engagement and training on product use and storage. Virax will provide product supply, documentation and technical support. ImmuneSelect is a commercially available research-use-only portfolio, distinct from the company's in-development ViraxImmune diagnostic platform.
Virax Biolabs Group Ltd reports that Chief Scientific Officer Clement Monteil directly holds five stock-option positions covering 60, 400, 800, 600 and 3,000 ordinary shares, with exercise prices of 310, 150, 17, 21.9 and 3.75, respectively. The options expire between December 7, 2032, and April 8, 2036. Footnotes state that each grant vests in equal thirds on scheduled annual dates and that vested portions become exercisable upon vesting.
Virax Biolabs Group Limited (VRAX) is restructuring senior management, eliminating the standalone Chief Operating Officer role and appointing Clement Monteil Acting Chief Scientific Officer for an initial six-month term, effective October 5, 2026. The company says the restructuring is designed to reduce operating expenditure and prioritize ViraxImmune development.
Dr. Nigel McCracken, whose COO position was made redundant, began paid garden leave on October 5, 2026; his employment is scheduled to end December 23, 2026, and he will remain a director. He will receive a statutory redundancy payment of £3,379.50 plus a payment in lieu of the balance of his three-month contractual notice period. Dr. Monteil has served as Head of Research and Development since 2022.
Virax Biolabs Group Limited (VRAX) has filed a resale prospectus covering up to 1,682,360 ordinary shares, all to be sold from time to time by existing security holders. These shares consist of 1,644,000 ordinary shares issuable upon exercise of new Series A and Series B preferred investment options and 38,360 shares issuable upon exercise of placement agent warrants. The new warrants have an exercise price of $6.00 per share and the placement agent warrants an exercise price of $7.50 per share, and become exercisable following shareholder approval of an authorized share increase on August 21, 2026, with expirations five years or eighteen months after September 3, 2026, as applicable.
The company will not receive proceeds from any resale of shares by the selling shareholders but may receive cash if the warrants are exercised, which it intends to use as working capital for general corporate purposes. Ordinary shares outstanding were 1,344,988 as of September 2, 2026; this is a baseline figure, not the amount being offered. Virax is a Cayman Islands holding company focused on T cell–based immune profiling and in vitro diagnostic technologies, qualifies as an emerging growth company and a foreign private issuer, and its ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX.
Virax Biolabs Group Ltd (VRAX) has amended its existing at-the-market equity program with H.C. Wainwright & Co., LLC by filing a new sticker prospectus supplement. The amendment increases the maximum aggregate offering amount of Ordinary Shares that may be sold through the Sales Agent under the program to $2,070,060.20. This amount is in addition to $3,658,152 of Ordinary Shares previously sold under the same Sales Agreement. The updated prospectus supplements and Base Prospectus form part of Virax’s effective Registration Statement on Form F-3, and a legal opinion from Ogier regarding the validity of the Ordinary Shares is included as an exhibit.
Virax Biolabs Group Limited (VRAX) updated its at-the-market equity program under its Form F-3 shelf registration, allowing the company to offer and sell up to $2,070,060.20 of ordinary shares from time to time through H.C. Wainwright & Co. under an existing At The Market Offering Agreement. This new capacity is based on General Instruction I.B.5 of Form F-3 and the company’s current public float. The update excludes approximately $3,658,152 of ordinary shares already sold under prior related prospectus supplements. Virax’s ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX, and the company is relying on emerging growth company and foreign private issuer reporting accommodations.
Virax Biolabs Group Limited (VRAX) has filed an amended Form F-3 to register for resale up to 1,682,360 ordinary shares, all to be sold from time to time by existing security holders. These shares consist of 1,644,000 New Warrant Shares and 38,360 Placement Agent Warrant Shares.
Virax will not receive proceeds from any resale of these shares, but may receive cash if investors exercise the underlying warrants, which carry exercise prices of $6.00 and $7.50 per share. Ordinary shares outstanding were 1,344,988 as of September 2, 2026, after a 1-for-25 share consolidation effective June 26, 2026.
Virax Biolabs Group Ltd (VRAX) held an Extraordinary General Meeting process in August 2026 to consider changes to its capital structure and governing documents. An initial meeting on August 14, 2026 lacked a quorum and was adjourned to August 21, 2026, where, under the Articles of Association, the shareholders present after 15 minutes (representing 8.94% of voting shares) constituted a quorum.
Shareholders approved an ordinary resolution to increase authorized share capital from US$50,000 (2,000,000 ordinary shares of US$0.025 par value) to US$12,500,000 (500,000,000 ordinary shares), by creating 498,000,000 additional authorized shares. The vote on this Share Capital Increase was 61,471 for, 54,414 against, and 4,342 abstain. A separate special resolution to adopt a fifth amended and restated memorandum and articles of association to reflect the revised authorized share capital and the effective date of a Share Consolidation did not receive the required two-thirds majority and was not approved, despite votes of 66,754 for, 53,203 against, and 270 abstain.